Similar articles

• Leuprolide: a review of its effects in animals and man.

  Drago JR, Rohner T, Santen R, Manni A, English H, Lipton A, Harvey H. Drago JR, et al. Br J Clin Pract. 1985 Feb;39(2):77-9. Br J Clin Pract. 1985. PMID: 3921048 No abstract available.
• The treatment of prostatic cancer by LH-RH agonist.

  Imai K, Yamanaka H, Yuasa H, Yoshida M, Asano M, Kaetsu I. Imai K, et al. Prog Clin Biol Res. 1987;243A:429-34. Prog Clin Biol Res. 1987. PMID: 3116552 No abstract available.
• Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.

  Santen RJ, Warner B. Santen RJ, et al. Urology. 1985 Feb;25(2 Suppl):53-7. Urology. 1985. PMID: 3918377
• Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.

  Thompson IM, Zeidman EJ, Rodriguez FR. Thompson IM, et al. J Urol. 1990 Dec;144(6):1479-80. doi: 10.1016/s0022-5347(17)39774-4. J Urol. 1990. PMID: 2122011 Review.
• [LHRH analogs--new possibilities in the treatment of prostatic cancer].

  Baranowska B. Baranowska B. Pol Tyg Lek. 1984 Jul 16-23;39(29-30):1009-12. Pol Tyg Lek. 1984. PMID: 6239145 Review. Polish. No abstract available.